GV20 Therapeutics Announces Oral Presentation on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024

2024-03-05

AACR会议免疫疗法临床1期

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that its abstract was selected for an oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.

Details of the oral presentation are below:

Title: "IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target"

Session Type: Minisymposium

Session Category: Immunology

Session Title: Immune Targets and Therapies

Session Date/Time: Monday Apr 8, 2024, 2:30 PM - 4:30 PM

Abstract Presentation Number: 3914

More information can be found on the 2024 AACR website.

ABOUT GV20 THERAPEUTICS

At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform the treatment of cancer. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA.

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

Business Contact

Ying Gong, Ph.D., CBO

[email protected]

Investor and Media Contact

Amy Conrad

Juniper Point

[email protected]

SOURCE GV20 Therapeutics

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构